Key Trends and Insights into the Antisense & RNAi Therapeutics Market: Growth Rate and Opportunities to 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the antisense & rnai therapeutics market size evolved in recent years?
The market size for antisense & RNAi therapeutics has seen a swift expansion in the preceding years. The market, valued at $1.75 billion in 2024, is expected to increase to $1.94 billion in 2025 with a compound annual growth rate (CAGR) of 11.2%. This considerable growth during the previous time can be credited to factors such as increased funding, technological advancements, a surge in healthcare spending, a rapidly aging population, and economic growth in newly marketable areas.
What are the predictions for the antisense & rnai therapeutics market size in the coming years?
The market size of antisense & RNAi therapeutics is set to experience a rapid expansion in the coming years. It’s projected to reach $3.18 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 13.1%. This predicted growth during the forecast period is largely due to increased access to healthcare, an escalating prevalence of cancer and the heightened need for antisense and RNAi therapeutics amidst the COVID-19 crisis. The forecast period will also see key trends such as intensified research and development into RNA therapeutics for rare diseases, the adoption of nanoparticles, the invention of advanced antisense and RNAi therapeutics, and strategic collaborations with different companies for product evolution and revenue growth.
Get your antisense & rnai therapeutics market report here!
What key factors are fueling the growth of the antisense & rnai therapeutics market?
The escalating incidences of coronary artery diseases, infectious diseases, and neurodegenerative disorders are anticipated to fuel the demand in the antisense & RNAi therapeutics market. Various neurodegenerative ailments are treated using gene suppression techniques such as RNA interference and antisense oligonucleotides, which help repair mutant genes. For example, a report released by the American Heart Association, an organization based in the US, illustrated that, in January 2024, the age-adjusted mortality rate from cardiovascular diseases rose by 4.0% from the past year, reaching 233.3 per 100,000 people. Hence, as the pervasiveness of numerous neurodegenerative and infectious diseases increases, so too is the antisense & RNAi therapeutics market projected to grow.
How is the global antisense & rnai therapeutics market divided into key segments?
The antisense & RNAi therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Who are the key firms paving the way for growth in the antisense & rnai therapeutics market?
Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical
Which trends are expected to transform the antisense & rnai therapeutics market?
Leading enterprises in the antisense & RNAi therapeutics market are initiating strategic measures, including alliances and partnerships, to maintain their position in an intensifying market. This tactical collaboration involves cooperation between two or more firms to meet a aligned goal. For example, in January 2023, Orbit Discovery Limited, an American company that offers peptide discovery services, collaborated with UK-based SanegeneBio Inc., which develops original RNAi-based medication. This partnership aims to identify tissue-specific delivery of RNA therapies for effective gene knockdown, with an objective to formulate a collection of advanced RNAi therapeutics. The alliance includes the identification of potential therapeutic targets and cell-based internalization studies. Sanegene has the choice to further advance these potential targets identified from the screening activities, utilizing Orbit’s unique technology for quick peptide lead discovery. Orbit Discovery’s exclusive peptide display platform allows the analysis of expansive peptide libraries, ultimately leading to the faster discovery of significant peptide leads through affinity and functional screens.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389
What regions are contributing significantly to the growth of the antisense & rnai therapeutics market?
North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Anti-Hypertensive Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Neurodegenerative Disorder Therapeutics Global Market Report 2024
Biosimilar Hormones Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
